Highly stereoselective hydrogenations—As key‐steps in the total synthesis of statins
Abstract
Statins are inhibitors of 3‐hydroxy‐3‐methyl‐glutaryl coenzyme A reductase (HMG‐CoA reductase) and became the standard of care for treatment of hypercholesterolemia because of their efficacy, safety, and long‐term benefits. They are administered as diastereo‐ and enantiomerically pure compounds. We summarize here two new approaches for the total synthesis of the most important representatives, atorvastatin, and rosuvastatin, based on highly stereoselective hydrogenations as key‐steps. Chirality 2010.Keywords
Funding Information
- Ratiopharm GmbH (Ulm)
This publication has 33 references indexed in Scilit:
- A New Approach to the Total Synthesis of RosuvastatinEuropean Journal of Organic Chemistry, 2008
- Synthesis and Highly Stereoselective Hydrogenation of the Statin Precursor Ethyl (5S)‐5,6‐Isopropylidenedioxy‐3‐oxohexanoateAdvanced Synthesis & Catalysis, 2006
- Synthesis of the Chiral Side Chain of Statins – Lactone versus Lactol PathwayEuropean Journal of Organic Chemistry, 2006
- Statins in the Treatment of Chronic Heart Failure: A Systematic ReviewPLOS Medicine, 2006
- Statin Safety: A Systematic ReviewThe American Journal of Cardiology, 2006
- Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease preventionAmerican Heart Journal, 2006
- Rosuvastatin is cost-effective compared with atorvastatin in reaching cholesterol goalsInternational Journal of Cardiology, 2005
- AtorvastatinDrugs, 2005
- Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysisBMJ, 2003
- Rapid Asymmetric Synthesis of Highly Functionalized C5 Chiral Synthons. Practical Preparation of trans-3-Hydroxy-D-ProlineSynlett, 1998